ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Use of GLP-1 Receptor Agonists in Kidney Transplant Recipients with Type 2 Diabetes

A. Kukla, J. Hill, M. Merzkani, A. Bentall, E. Lorenz, W. Park, P. Shah, N. Issa, M. Stegall

Mayo Clinic, Rochester, MN

Meeting: 2019 American Transplant Congress

Abstract number: C177

Keywords: Drug interaction, Hyperglycemia, Kidney transplantation, Weight

Session Information

Session Name: Poster Session C: Kidney: Cardiovascular and Metabolic

Session Type: Poster Session

Date: Monday, June 3, 2019

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: GLP-1 receptor agonists have been shown to improve glucose control and diabetes-related comorbidities, including obesity, cardiovascular disease and chronic kidney disease, in non-transplant patients. Although GLP-1 receptor agonists represent a promising therapeutic approach to diabetes after solid-organ transplant, the safety and efficacy of these drugs in transplant recipients have not been adequately studied. In particular, there are concerns regarding gastrointestinal (GI) side effects and absorption of the transplant medications in patients taking GLP-1 receptor agonists.

*Methods: Retrospective analysis was performed on 17 transplant recipients who were started on GLP-1 receptor agonists: 14 received kidney transplant alone, 2 combined heart-kidney transplant and one combined liver- kidney transplant. Mean time post transplant was 161.5 months +/- 140. The most common reason to start the medication was to promote the weight loss and to improve blood glucose control. 14 recipients received Liraglutide, 1 Exenatide and 2 Dulaglutide.

*Results: Among the cohort, 64% were male with a median age of 51.7 years [40-62] and BMI of 35.8 ±4.6 kg/m2. Mean eGFR was 50 ± 13.2 ml/min/1.73 m2 at the time of initiation of GLP-1 receptor agonists. Patients were on the following immunosuppressive regimen: 13 patients: Tacrolimus, CellCept and prednisone, 1 patient: Tacrolimus only, 2 patients: Tacrolimus and CellCept. Three patients (17%) discontinued GLP-1 receptor agonist within a month of the initiation; 2 of them due to GI side effects and 1 required conversion to insulin. Of the remaining patients, majority were able to tolerate GLP-1 receptor agonists without any significant problems and were taking the following doses by the end of the observation: Liraglutide 1.8 mg daily (7 patients), 1.2 mg daily (5 patients), 0.6 mg daily (1 patient), Exenatide 2 mg weekly (1 patient) Dulaglutide 1.5 mg (1 patient) and 0.5 mg (1 patient) weekly. Weight loss and decreased insulin requirements were noted by the end of follow up, while kidney function remained stable (Table). None of the patients experienced acute rejection during the follow up period. No change was noted in Tacrolimus dosing.

Change in patients’ characteristics following GLP-1 agonist initiation
Change in weight in kgs (mean)SD -4.6+/-7.2
Change in HbA1C (mean)SD -0.45 +/- 0.69
Change in insulin requirements (mean)SD -7.3 +/- 16
Change in AGFR (mean)SD 0 +/- 0.6
Change in creatinine (mean)SD 0.06+/- 0.5
Change in GFR(mean) SD 5.7+/-13.3

*Conclusions: GLP-1 receptor agonists may be a safe and effective treatment for solid-organ transplant recipients with type 2 diabetes. Discontinuation rate due to the side effects was low and similar to the non-transplant population. More studies are needed to evaluate cardiovascular and renal benefits of GLP-1 receptor agonists in this population.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kukla A, Hill J, Merzkani M, Bentall A, Lorenz E, Park W, Shah P, Issa N, Stegall M. Use of GLP-1 Receptor Agonists in Kidney Transplant Recipients with Type 2 Diabetes [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/use-of-glp-1-receptor-agonists-in-kidney-transplant-recipients-with-type-2-diabetes/. Accessed May 8, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences